{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:30:17Z","timestamp":1793313017394,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40259-022-00519-9","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T06:03:41Z","timestamp":1646633021000},"page":"105-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic"],"prefix":"10.1007","volume":"36","author":[{"given":"Morgan E.","family":"Rook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-5008","authenticated-orcid":false,"given":"Amber L.","family":"Southwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"issue":"3","key":"519_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/bf00225192","volume":"95","author":"KE De Rooij","year":"1995","unstructured":"De Rooij KE, De Koning Gans PA, Roos RA, Van Ommen GJ, Den Dunnen JT. Somatic expansion of the (CAG)n repeat in Huntington disease brains. Hum Genet. 1995;95(3):270\u20134. https:\/\/doi.org\/10.1007\/bf00225192.","journal-title":"Hum Genet"},{"issue":"3","key":"519_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1172\/JCI17742","volume":"111","author":"AB Young","year":"2003","unstructured":"Young AB. Huntingtin in health and disease. J Clin Invest. 2003;111(3):299\u2013302. https:\/\/doi.org\/10.1172\/JCI17742.","journal-title":"J Clin Invest"},{"issue":"3","key":"519_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/ajmg.a.20190","volume":"119A","author":"L Djouss\u00e9","year":"2003","unstructured":"Djouss\u00e9 L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C, et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A. 2003;119A(3):279\u201382. https:\/\/doi.org\/10.1002\/ajmg.a.20190.","journal-title":"Am J Med Genet A"},{"issue":"4","key":"519_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"J-M Lee","year":"2019","unstructured":"Lee J-M, Correia K, Loupe J, Kim K-H, Barker D, Hong EP, et al. CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. Cell. 2019;178(4):887-900.e14. https:\/\/doi.org\/10.1016\/j.cell.2019.06.036.","journal-title":"Cell"},{"issue":"1","key":"519_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83\u201398.","journal-title":"Lancet Neurol"},{"issue":"1","key":"519_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell. 2000;101(1):57\u201366. https:\/\/doi.org\/10.1016\/s0092-8674(00)80623-6.","journal-title":"Cell"},{"issue":"16","key":"519_CR7","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, et al. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. PNAS. 2005;102(16):5820\u20135. https:\/\/doi.org\/10.1073\/pnas.0501507102.","journal-title":"PNAS"},{"issue":"4","key":"519_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice. Mol Ther. 2005;12(4):618\u201333.","journal-title":"Mol Ther"},{"issue":"3","key":"519_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","volume":"53","author":"Y-L Wang","year":"2005","unstructured":"Wang Y-L, Liu W, Wada E, Murata M, Wada K, Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington\u2019s disease by siRNA. Neurosci Res. 2005;53(3):241\u20139.","journal-title":"Neurosci Res"},{"key":"519_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259\u201393. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"519_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","volume":"18","author":"AL Southwell","year":"2012","unstructured":"Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med. 2012;18(11):634\u201343. https:\/\/doi.org\/10.1016\/j.molmed.2012.09.001.","journal-title":"Trends Mol Med"},{"issue":"7","key":"519_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/abbs\/gmw044","volume":"48","author":"Y Wu","year":"2016","unstructured":"Wu Y, Lu J, Kang T. Human single-stranded DNA binding proteins: guardians of genome stability. Acta Biochim Biophys Sin. 2016;48(7):671\u20137. https:\/\/doi.org\/10.1093\/abbs\/gmw044.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"4","key":"519_CR13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46(4):1584\u2013600. https:\/\/doi.org\/10.1093\/nar\/gkx1239.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"519_CR14","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","volume":"48","author":"ST Crooke","year":"2020","unstructured":"Crooke ST, Vickers TA, Liang X-H. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020;48(10):5235\u201353. https:\/\/doi.org\/10.1093\/nar\/gkaa299.","journal-title":"Nucleic Acids Res"},{"key":"519_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12883-016-0564-9","volume":"16","author":"SM LeVine","year":"2016","unstructured":"LeVine SM. Albumin and multiple sclerosis. BMC Neurol. 2016;16:47. https:\/\/doi.org\/10.1186\/s12883-016-0564-9.","journal-title":"BMC Neurol"},{"issue":"22","key":"519_CR16","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1016\/S0960-894X(98)00591-5","volume":"8","author":"W Zhou","year":"1998","unstructured":"Zhou W, Agrawal S. Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg Med Chem Lett. 1998;8(22):3269\u201374. https:\/\/doi.org\/10.1016\/S0960-894X(98)00591-5.","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"519_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0006-2952(99)00294-4","volume":"58","author":"DS Pisetsky","year":"1999","unstructured":"Pisetsky DS, Reich CF. Influence of backbone chemistry on immune activation by synthetic oligonucleotides. Biochem Pharmacol. 1999;58(12):1981\u20138. https:\/\/doi.org\/10.1016\/S0006-2952(99)00294-4.","journal-title":"Biochem Pharmacol"},{"key":"519_CR18","unstructured":"(TGA) TTGA. Australian Public Assessment Report for nusinersen (as heptadecasodium). Commonwealth of Australia: Australian Government Department of Health Therapeutic Goods Administration (TGA); 2018."},{"issue":"24","key":"519_CR19","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1093\/nar\/23.24.5000","volume":"23","author":"M Koziolkiewicz","year":"1995","unstructured":"Koziolkiewicz M, Krakowiak A, Kwinkowski M, Boczkowska M, Stec WJ. Stereodifferentiation\u2014the effect of P chirality of oligo (nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res. 1995;23(24):5000\u20135. https:\/\/doi.org\/10.1093\/nar\/23.24.5000.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"519_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/nar\/gkaa031","volume":"48","author":"ME \u00d8stergaard","year":"2020","unstructured":"\u00d8stergaard ME, De Hoyos CL, Wan WB, Shen W, Low A, Berdeja A, et al. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Res. 2020;48(4):1691\u2013700. https:\/\/doi.org\/10.1093\/nar\/gkaa031.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"519_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0968-0896(99)00275-8","volume":"8","author":"D Yu","year":"2000","unstructured":"Yu D, Kandimalla ER, Roskey A, Zhao Q, Chen L, Chen J, et al. Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. Bioorg Med Chem. 2000;8(1):275\u201384. https:\/\/doi.org\/10.1016\/S0968-0896(99)00275-8.","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"519_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Butler DCD, Svrzikapa N, Mohapatra S, Zlatev I, Sah DWY, et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol. 2017;35(9):845\u201351. https:\/\/doi.org\/10.1038\/nbt.3948.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"519_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0009-9236(96)90171-X","volume":"60","author":"K Hartigan-Go","year":"1996","unstructured":"Hartigan-Go K, Bateman DN, Daly AK, Thomas SHL. Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther. 1996;60(1):89\u201398. https:\/\/doi.org\/10.1016\/S0009-9236(96)90171-X.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"519_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2165\/00002018-199308020-00005","volume":"8","author":"AK Scott","year":"1993","unstructured":"Scott AK. Stereoisomers and drug toxicity. The value of single stereoisomer therapy. Drug Saf. 1993;8(2):149\u201359. https:\/\/doi.org\/10.2165\/00002018-199308020-00005.","journal-title":"Drug Saf."},{"issue":"12","key":"519_CR25","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1039\/c1cs15102a","volume":"40","author":"N Oka","year":"2011","unstructured":"Oka N, Wada T. Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. Chem Soc Rev. 2011;40(12):5829\u201343. https:\/\/doi.org\/10.1039\/c1cs15102a.","journal-title":"Chem Soc Rev"},{"issue":"19","key":"519_CR26","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1016\/j.tetasy.2006.10.014","volume":"17","author":"K Huang","year":"2006","unstructured":"Huang K, Breitbach ZS, Armstrong DW. Enantiomeric impurities in chiral synthons, catalysts, and auxiliaries. Part 3. Tetrahedron Asymmetry. 2006;17(19):2821\u201332. https:\/\/doi.org\/10.1016\/j.tetasy.2006.10.014.","journal-title":"Tetrahedron Asymmetry"},{"issue":"1","key":"519_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0167-4781(99)00138-4","volume":"1489","author":"M Manoharan","year":"1999","unstructured":"Manoharan M. 2\u2019-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta. 1999;1489(1):117\u201330. https:\/\/doi.org\/10.1016\/s0167-4781(99)00138-4.","journal-title":"Biochim Biophys Acta"},{"issue":"19","key":"519_CR28","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","volume":"268","author":"BP Monia","year":"1993","unstructured":"Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, et al. Evaluation of 2\u2032-modified oligonucleotides containing 2\u2019-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993;268(19):14514\u201322.","journal-title":"J Biol Chem"},{"key":"519_CR29","unstructured":"Wave. Patent 10,724,035: Oligonucleotide compositions and methods thereof. 2017."},{"issue":"9","key":"519_CR30","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/cbdv.201100081","volume":"8","author":"TP Prakash","year":"2011","unstructured":"Prakash TP. An overview of sugar-modified oligonucleotides for antisense therapeutics. Chem Biodivers. 2011;8(9):1616\u201341. https:\/\/doi.org\/10.1002\/cbdv.201100081.","journal-title":"Chem Biodivers"},{"issue":"24","key":"519_CR31","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med. 2019;380(24):2307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1900907.","journal-title":"N Engl J Med"},{"key":"519_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2019.10.011","author":"C Kay","year":"2019","unstructured":"Kay C, Collins JA, Caron NS, Agostinho LA, Findlay-Black H, Casal L, et al. A comprehensive haplotype targeting strategy for allele-specific HTT suppression in Huntington disease. Am J Human Genet. 2019. https:\/\/doi.org\/10.1016\/j.ajhg.2019.10.011.","journal-title":"Am J Human Genet"},{"issue":"5222","key":"519_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.7618107","volume":"269","author":"M Duyao","year":"1995","unstructured":"Duyao M, Auerbach A, Ryan A, Persichetti F, Barnes G, McNeil S, et al. Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh. Science. 1995;269(5222):407\u201310. https:\/\/doi.org\/10.1126\/science.7618107.","journal-title":"Science"},{"issue":"5","key":"519_CR34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir J, Floresco SB, O\u2019Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81(5):811\u201323. https:\/\/doi.org\/10.1016\/0092-8674(95)90542-1.","journal-title":"Cell"},{"issue":"2","key":"519_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ng1095-155","volume":"11","author":"S Zeitlin","year":"1995","unstructured":"Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue. Nat Genet. 1995;11(2):155\u201363. https:\/\/doi.org\/10.1038\/ng1095-155.","journal-title":"Nat Genet"},{"issue":"1","key":"519_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF02257483","volume":"20","author":"CM Ambrose","year":"1994","unstructured":"Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, et al. Structure and expression of the Huntington\u2019s disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet. 1994;20(1):27\u201338. https:\/\/doi.org\/10.1007\/BF02257483.","journal-title":"Somat Cell Mol Genet"},{"key":"519_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-2164-8-126","volume":"8","author":"SL Butland","year":"2007","unstructured":"Butland SL, Devon RS, Huang Y, Mead C-L, Meynert AM, Neal SJ, et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genom. 2007;8:126. https:\/\/doi.org\/10.1186\/1471-2164-8-126.","journal-title":"BMC Genom."},{"issue":"6","key":"519_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"B Kordasiewicz Holly","year":"2012","unstructured":"Kordasiewicz Holly B, Stanek Lisa M, Wancewicz Edward V, Mazur C, McAlonis Melissa M, Pytel Kimberly A, et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031\u201344. https:\/\/doi.org\/10.1016\/j.neuron.2012.05.009.","journal-title":"Neuron"},{"issue":"3","key":"519_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet. 2009;84(3):351\u201366.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"519_CR40","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol. 2009;19(9):774\u20138.","journal-title":"Curr Biol"},{"issue":"12","key":"519_CR41","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178\u201385. https:\/\/doi.org\/10.1038\/mt.2011.201.","journal-title":"Mol Ther"},{"issue":"21","key":"519_CR42","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","author":"ME \u00d8stergaard","year":"2013","unstructured":"\u00d8stergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 2013;41(21):9634\u201350. https:\/\/doi.org\/10.1093\/nar\/gkt725.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"519_CR43","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/mt.2014.153","volume":"22","author":"AL Southwell","year":"2014","unstructured":"Southwell AL, Skotte NH, Kordasiewicz HB, \u00d8stergaard ME, Watt AT, Carroll JB, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther. 2014;22(12):2093\u2013106. https:\/\/doi.org\/10.1038\/mt.2014.153.","journal-title":"Mol Ther"},{"key":"519_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3959","author":"AL Southwell","year":"2018","unstructured":"Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aar3959.","journal-title":"Sci Transl Med."},{"issue":"1","key":"519_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/cge.12385","volume":"86","author":"C Kay","year":"2014","unstructured":"Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clin Genet. 2014;86(1):29\u201336.","journal-title":"Clin Genet"},{"issue":"11","key":"519_CR46","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/mt.2015.128","volume":"23","author":"C Kay","year":"2015","unstructured":"Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, et al. Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European Ancestry. Mol Ther. 2015;23(11):1759\u201371. https:\/\/doi.org\/10.1038\/mt.2015.128.","journal-title":"Mol Ther"},{"issue":"4","key":"519_CR47","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ng1297-404","volume":"17","author":"JK White","year":"1997","unstructured":"White JK, Auerbach W, Duyao MP, Vonsattel J-P, Gusella JF, Joyner AL, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington\u2019s disease CAG expansion. Nat Genet. 1997;17(4):404\u201310. https:\/\/doi.org\/10.1038\/ng1297-404.","journal-title":"Nat Genet"},{"issue":"12","key":"519_CR48","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/ejhg.2016.74","volume":"24","author":"LH Rodan","year":"2016","unstructured":"Rodan LH, Cohen J, Fatemi A, Gillis T, Lucente D, Gusella J, et al. A novel neurodevelopmental disorder associated with compound heterozygous variants in the huntingtin gene. Eur J Hum Genet. 2016;24(12):1826\u20137. https:\/\/doi.org\/10.1038\/ejhg.2016.74.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"519_CR49","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/81593","volume":"26","author":"I Dragatsis","year":"2000","unstructured":"Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 2000;26(3):300\u20136. https:\/\/doi.org\/10.1038\/81593.","journal-title":"Nat Genet"},{"issue":"12","key":"519_CR50","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1073\/pnas.1524575113","volume":"113","author":"G Wang","year":"2016","unstructured":"Wang G, Liu X, Gaertig MA, Li S, Li X-J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci. 2016;113(12):3359\u201364. https:\/\/doi.org\/10.1073\/pnas.1524575113.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"519_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006846","volume":"13","author":"P Dietrich","year":"2017","unstructured":"Dietrich P, Johnson IM, Alli S, Dragatsis I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet. 2017;13(7): e1006846. https:\/\/doi.org\/10.1371\/journal.pgen.1006846.","journal-title":"PLoS Genet"},{"issue":"7806","key":"519_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41586-020-2200-5","volume":"581","author":"GHD Poplawski","year":"2020","unstructured":"Poplawski GHD, Kawaguchi R, Van Niekerk E, Lu P, Mehta N, Canete P, et al. Injured adult neurons regress to an embryonic transcriptional growth state. Nature. 2020;581(7806):77\u201382. https:\/\/doi.org\/10.1038\/s41586-020-2200-5.","journal-title":"Nature"},{"issue":"6505","key":"519_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.aax3338","volume":"369","author":"M Barnat","year":"2020","unstructured":"Barnat M, Capizzi M, Aparicio E, Boluda S, Wennagel D, Kacher R, et al. Huntington\u2019s disease alters human neurodevelopment. Science. 2020;369(6505):787\u201393. https:\/\/doi.org\/10.1126\/science.aax3338.","journal-title":"Science"},{"issue":"3","key":"519_CR54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.neuron.2010.06.027","volume":"67","author":"JD Godin","year":"2010","unstructured":"Godin JD, Colombo K, Molina-Calavita M, Keryer G, Zala D, Charrin BC, et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron. 2010;67(3):392\u2013406. https:\/\/doi.org\/10.1016\/j.neuron.2010.06.027.","journal-title":"Neuron"},{"issue":"1","key":"519_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107865","volume":"32","author":"F Agasse","year":"2020","unstructured":"Agasse F, Mendez-David I, Christaller W, Carpentier R, Braz BY, David DJ, et al. Chronic corticosterone elevation suppresses adult hippocampal neurogenesis by hyperphosphorylating Huntingtin. Cell Rep. 2020;32(1): 107865. https:\/\/doi.org\/10.1016\/j.celrep.2020.107865.","journal-title":"Cell Rep"},{"issue":"2","key":"519_CR56","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nbd.2010.09.012","volume":"41","author":"JM Simpson","year":"2011","unstructured":"Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, et al. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol Dis. 2011;41(2):249\u201360. https:\/\/doi.org\/10.1016\/j.nbd.2010.09.012.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"519_CR57","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.cell.2014.01.044","volume":"156","author":"A Ernst","year":"2014","unstructured":"Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, et al. Neurogenesis in the striatum of the adult human brain. Cell. 2014;156(5):1072\u201383. https:\/\/doi.org\/10.1016\/j.cell.2014.01.044.","journal-title":"Cell"},{"issue":"6","key":"519_CR58","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1074\/jbc.M113.513945","volume":"289","author":"MP Parsons","year":"2014","unstructured":"Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, et al. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin. J Biol Chem. 2014;289(6):3518\u201328. https:\/\/doi.org\/10.1074\/jbc.M113.513945.","journal-title":"J Biol Chem"},{"issue":"1","key":"519_CR59","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M, Dompierre JP, Rangone H, Cordeli\u00e8res FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118(1):127\u201338. https:\/\/doi.org\/10.1016\/j.cell.2004.06.018.","journal-title":"Cell"},{"issue":"3","key":"519_CR60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cell.2012.12.029","volume":"152","author":"D Zala","year":"2013","unstructured":"Zala D, Hinckelmann M-V, Yu H, da Cunha Marcel ML, Liot G, Cordeli\u00e8res Fabrice P, et al. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell. 2013;152(3):479\u201391. https:\/\/doi.org\/10.1016\/j.cell.2012.12.029.","journal-title":"Cell"},{"issue":"4","key":"519_CR61","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1083\/jcb.200509091","volume":"172","author":"A Pal","year":"2006","unstructured":"Pal A, Severin F, Lommer B, Shevchenko A, Zerial M. Huntingtin\u2013HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington\u2019s disease. J Cell Biol. 2006;172(4):605\u201318. https:\/\/doi.org\/10.1083\/jcb.200509091.","journal-title":"J Cell Biol"},{"issue":"47","key":"519_CR62","doi-asserted-by":"publisher","first-page":"16889","DOI":"10.1073\/pnas.1420103111","volume":"111","author":"J Ochaba","year":"2014","unstructured":"Ochaba J, Lukacsovich T, Csikos G, Zheng S, Margulis J, Salazar L, et al. Potential function for the huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci. 2014;111(47):16889\u201394. https:\/\/doi.org\/10.1073\/pnas.1420103111.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"519_CR63","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ncb3101","volume":"17","author":"YN Rui","year":"2015","unstructured":"Rui YN, Xu Z, Patel B, Chen Z, Chen D, Tito A, et al. Huntingtin functions as a scaffold for selective macroautophagy. Nat Cell Biol. 2015;17(3):262\u201375. https:\/\/doi.org\/10.1038\/ncb3101.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"519_CR64","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1523\/JNEUROSCI.1870-13.2014","volume":"34","author":"YC Wong","year":"2014","unstructured":"Wong YC, Holzbaur ELF. The regulation of autophagosome dynamics by Huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation. J Neurosci. 2014;34(4):1293. https:\/\/doi.org\/10.1523\/JNEUROSCI.1870-13.2014.","journal-title":"J Neurosci"},{"key":"519_CR65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nbd.2015.09.008","volume":"90","author":"P Guedes-Dias","year":"2016","unstructured":"Guedes-Dias P, Pinho BR, Soares TR, de Proen\u00e7a J, Duchen MR, Oliveira JMA. Mitochondrial dynamics and quality control in Huntington\u2019s disease. Neurobiol Dis. 2016;90:51\u20137. https:\/\/doi.org\/10.1016\/j.nbd.2015.09.008.","journal-title":"Neurobiol Dis"},{"key":"519_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1728096","author":"S Franco-Iborra","year":"2020","unstructured":"Franco-Iborra S, Plaza-Zabala A, Montpeyo M, Sebastian D, Vila M, Martinez-Vicente M. Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease. Autophagy. 2020. https:\/\/doi.org\/10.1080\/15548627.2020.1728096.","journal-title":"Autophagy"},{"issue":"8","key":"519_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023211","volume":"6","author":"J Park","year":"2011","unstructured":"Park J, Lee J, Choi C. Mitochondrial network determines intracellular ROS dynamics and sensitivity to oxidative stress through switching inter-mitochondrial messengers. PLoS ONE. 2011;6(8): e23211. https:\/\/doi.org\/10.1371\/journal.pone.0023211.","journal-title":"PLoS ONE"},{"issue":"21","key":"519_CR68","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1093\/hmg\/ddm217","volume":"16","author":"RS Atwal","year":"2007","unstructured":"Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet. 2007;16(21):2600\u201315. https:\/\/doi.org\/10.1093\/hmg\/ddm217.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"519_CR69","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1073\/pnas.1314421111","volume":"111","author":"B Rotblat","year":"2014","unstructured":"Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S, et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc Natl Acad Sci USA. 2014;111(8):3032\u20137. https:\/\/doi.org\/10.1073\/pnas.1314421111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"519_CR70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/hmg\/ddx394","volume":"27","author":"DE Ehrnhoefer","year":"2018","unstructured":"Ehrnhoefer DE, Southwell AL, Sivasubramanian M, Qiu X, Villanueva EB, Xie Y, et al. HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Hum Mol Genet. 2018;27(2):239\u201353. https:\/\/doi.org\/10.1093\/hmg\/ddx394.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"519_CR71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/hmg\/ddw395","volume":"26","author":"T Maiuri","year":"2017","unstructured":"Maiuri T, Mocle AJ, Hung CL, Xia J, van Roon-Mom WMC, Truant R. Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex. Hum Mol Genet. 2017;26(2):395\u2013406. https:\/\/doi.org\/10.1093\/hmg\/ddw395.","journal-title":"Hum Mol Genet"},{"key":"519_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.524369","author":"E Machiela","year":"2020","unstructured":"Machiela E, Jeloka R, Caron NS, Mehta S, Schmidt ME, Baddeley HJE, et al. The interaction of aging and cellular stress contributes to pathogenesis in mouse and human Huntington disease neurons. Front Aging Neurosci. 2020. https:\/\/doi.org\/10.3389\/fnagi.2020.524369.","journal-title":"Front Aging Neurosci."},{"key":"519_CR73","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neuroscience.2016.03.031","volume":"325","author":"C Connolly","year":"2016","unstructured":"Connolly C, Magnusson-Lind A, Lu G, Wagner PK, Southwell AL, Hayden MR, et al. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience. 2016;325:74\u201388.","journal-title":"Neuroscience"},{"issue":"11","key":"519_CR74","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1093\/hmg\/ddv080","volume":"24","author":"VB Mattis","year":"2015","unstructured":"Mattis VB, Tom C, Akimov S, Saeedian J, \u00d8stergaard ME, Southwell AL, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet. 2015;24(11):3257\u201371. https:\/\/doi.org\/10.1093\/hmg\/ddv080.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"519_CR75","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1471-4159.2005.03605.x","volume":"96","author":"BR Leavitt","year":"2006","unstructured":"Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem. 2006;96(4):1121\u20139. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03605.x.","journal-title":"J Neurochem"},{"issue":"10","key":"519_CR76","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/hmg\/ddr075","volume":"20","author":"L Munsie","year":"2011","unstructured":"Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, Bamburg JR, et al. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet. 2011;20(10):1937\u201351. https:\/\/doi.org\/10.1093\/hmg\/ddr075.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"519_CR77","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/hmg\/ddu460","volume":"24","author":"S Nath","year":"2015","unstructured":"Nath S, Munsie LN, Truant R. A huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington\u2019s disease. Hum Mol Genet. 2015;24(2):450\u201362. https:\/\/doi.org\/10.1093\/hmg\/ddu460.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"519_CR78","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol Ther. 2011;19(12):2152\u201362. https:\/\/doi.org\/10.1038\/mt.2011.219.","journal-title":"Mol Ther"},{"issue":"4","key":"519_CR79","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135(4):1197\u2013209. https:\/\/doi.org\/10.1093\/brain\/awr333.","journal-title":"Brain"},{"issue":"1","key":"519_CR80","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","volume":"233","author":"DK Stiles","year":"2012","unstructured":"Stiles DK, Zhang Z, Ge P, Nelson B, Grondin R, Ai Y, et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol. 2012;233(1):463\u201371. https:\/\/doi.org\/10.1016\/j.expneurol.2011.11.020.","journal-title":"Exp Neurol"},{"issue":"17","key":"519_CR81","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1093\/hmg\/ddw212","volume":"25","author":"AL Southwell","year":"2016","unstructured":"Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, et al. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum Mol Genet. 2016;25(17):3654\u201375. https:\/\/doi.org\/10.1093\/hmg\/ddw212.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"519_CR82","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nn.4014","volume":"18","author":"K Be\u010danovi\u0107","year":"2015","unstructured":"Be\u010danovi\u0107 K, N\u00f8rrem\u00f8lle A, Neal SJ, Kay C, Collins JA, Arenillas D, et al. A SNP in the HTT promoter alters NF-\u03baB binding and is a bidirectional genetic modifier of Huntington disease. Nat Neurosci. 2015;18(6):807\u201316. https:\/\/doi.org\/10.1038\/nn.4014.","journal-title":"Nat Neurosci"},{"issue":"1","key":"519_CR83","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/nar\/gkz976","volume":"48","author":"NS Caron","year":"2020","unstructured":"Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, et al. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020;48(1):36\u201354. https:\/\/doi.org\/10.1093\/nar\/gkz976.","journal-title":"Nucleic Acids Res"},{"key":"519_CR84","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008.","journal-title":"Adv Drug Deliv Rev"},{"key":"519_CR85","unstructured":"Schobel SA. Preliminary results from a 15-month open-label extension (OLE) study investigating RG6042 huntingtin protein (HTT) antisense oligonucleotide (ASO) in adults with manifest Huntington's disease (HD). In: CHDI 15th annual HD therapeutics conference. 2020."},{"key":"519_CR86","unstructured":"Schobel SA. Preliminary results from GENERATION HD1, a phase III trial of tominersen in individuals with manifest HD. In: CHDI 16th annual HD therapeutics conference. 2021."},{"key":"519_CR87","unstructured":"Roche. Roche provides update on tominersen programme in manifest Huntington's disease. Basel. 2021."},{"key":"519_CR88","unstructured":"WAVE. Wave life sciences announces topline data and addition of higher dose cohort in ongoing phase of 1b\/2a PRECISION-HD2 trial in Huntington\u2019s disease. Cambridge. 2019."},{"key":"519_CR89","unstructured":"Wave. Wave life sciences provides update on phase 1b\/2a PRECISION-HD Trials. Cambridge. 2021."},{"key":"519_CR90","unstructured":"Wave. Wave life sciences reports fourth quarter and full year 2019 financial results and provides business update. Cambridge. 2020."},{"key":"519_CR91","unstructured":"Wave. Wave life sciences highlights pipeline progress and expansion leveraging new PN backbone chemistry modifications. Cambridge. 2021."},{"key":"519_CR92","unstructured":"Viglietta V. A Ph1b\/2a study of WVE-003, an investigational allele-selective, mHTT-lowering oligonucleotide for the treatment of early manifest Huntington\u2019s disease, and review of PRECISION-HD results. In: CHDI 16th annual HD therapeutics conference: wave life sciences. 2021."},{"key":"519_CR93","unstructured":"Wave. Wave life sciences reports third quarter 2020 financial results and provides business update. Cambridge. 2020."},{"issue":"8","key":"519_CR94","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/jci99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558\u201367. https:\/\/doi.org\/10.1172\/jci99081.","journal-title":"J Clin Invest"},{"issue":"1","key":"519_CR95","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","volume":"61","author":"CF Bennett","year":"2021","unstructured":"Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense drugs make sense for neurological diseases. Annu Rev Pharmacol Toxicol. 2021;61(1):831\u201352. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010919-023738.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"519_CR96","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1176\/appi.ajp.2015.14121551","volume":"173","author":"EA Epping","year":"2016","unstructured":"Epping EA, Kim JI, Craufurd D, Brashers-Krug TM, Anderson KE, McCusker E, et al. Longitudinal psychiatric symptoms in prodromal Huntington\u2019s disease: a decade of data. Am J Psychiatry. 2016;173(2):184\u201392. https:\/\/doi.org\/10.1176\/appi.ajp.2015.14121551.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"519_CR97","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874\u201380. https:\/\/doi.org\/10.1136\/jnnp.2007.128728.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"519_CR98","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","volume":"19","author":"RI Scahill","year":"2020","unstructured":"Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 2020;19(6):502\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(20)30143-5.","journal-title":"Lancet Neurol"},{"issue":"3","key":"519_CR99","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuroimage.2007.12.053","volume":"40","author":"C Lebel","year":"2008","unstructured":"Lebel C, Walker L, Leemans A, Phillips L, Beaulieu C. Microstructural maturation of the human brain from childhood to adulthood. Neuroimage. 2008;40(3):1044\u201355. https:\/\/doi.org\/10.1016\/j.neuroimage.2007.12.053.","journal-title":"Neuroimage"},{"key":"519_CR100","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neurobiolaging.2021.07.013","volume":"107","author":"B Lim","year":"2021","unstructured":"Lim B, Gr\u00f8ntvedt GR, Bathala P, Kale SS, Campbell CT, Stengelin M, et al. CSF neurofilament light may predict progression from amnestic mild cognitive impairment to Alzheimer\u2019s disease dementia. Neurobiol Aging. 2021;107:78\u201385. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.07.013.","journal-title":"Neurobiol Aging"},{"key":"519_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327129","author":"S Halbgebauer","year":"2021","unstructured":"Halbgebauer S, Steinacker P, Verde F, Weishaupt J, Oeckl P, von Arnim C, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry. 2021. https:\/\/doi.org\/10.1136\/jnnp-2021-327129.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"519_CR102","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211039104","author":"I Rosenstein","year":"2021","unstructured":"Rosenstein I, Axelsson M, Novakova L, Blennow K, Zetterberg H, Lycke J. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. Mult Scler (Houndmills, Basingstoke, England). 2021. https:\/\/doi.org\/10.1177\/13524585211039104.","journal-title":"Mult Scler (Houndmills, Basingstoke, England)."},{"issue":"1","key":"519_CR103","doi-asserted-by":"publisher","first-page":"14114","DOI":"10.1038\/s41598-017-14179-1","volume":"7","author":"R Soylu-Kucharz","year":"2017","unstructured":"Soylu-Kucharz R, Sandelius \u00c5, Sj\u00f6gren M, Blennow K, Wild EJ, Zetterberg H, et al. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington\u2019s disease R6\/2 mice. Sci Rep. 2017;7(1):14114. https:\/\/doi.org\/10.1038\/s41598-017-14179-1.","journal-title":"Sci Rep"},{"key":"519_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/currents.hd.280c8f9f7d9fa4f7f0c883d9f8e807da","author":"N Szejko","year":"2018","unstructured":"Szejko N, Pic\u00f3n C, Garc\u00eda-Caldentey J, de Yebenes JG, Alvarez-Cerme\u00f1o JC, Villar LM, et al. Quantification of the light subunit of neurofilament protein in cerebrospinal fluid of Huntington\u2019s disease patients. PLoS Curr. 2018. https:\/\/doi.org\/10.1371\/currents.hd.280c8f9f7d9fa4f7f0c883d9f8e807da.","journal-title":"PLoS Curr."},{"issue":"1","key":"519_CR105","doi-asserted-by":"publisher","first-page":"12166","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell AL, Smith SEP, Davis TR, Caron NS, Villanueva EB, Xie Y, et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015;5(1):12166. https:\/\/doi.org\/10.1038\/srep12166.","journal-title":"Sci Rep"},{"issue":"4","key":"519_CR106","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1523\/JNEUROSCI.1865-20.2020","volume":"41","author":"NS Caron","year":"2021","unstructured":"Caron NS, Banos R, Yanick C, Aly AE, Byrne LM, Smith ED, et al. Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease. J Neurosci. 2021;41(4):780. https:\/\/doi.org\/10.1523\/JNEUROSCI.1865-20.2020.","journal-title":"J Neurosci"},{"issue":"1","key":"519_CR107","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia Luis F, Preische O, Schelle J, Apel A, Kaeser Stephan A, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91(1):56\u201366. https:\/\/doi.org\/10.1016\/j.neuron.2016.05.018.","journal-title":"Neuron"},{"issue":"6","key":"519_CR108","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","journal-title":"Nat Med"},{"issue":"1","key":"519_CR109","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","volume":"7","author":"A Neueder","year":"2017","unstructured":"Neueder A, Landles C, Ghosh R, Howland D, Myers RH, Faull RLM, et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients. Sci Rep. 2017;7(1):1307. https:\/\/doi.org\/10.1038\/s41598-017-01510-z.","journal-title":"Sci Rep"},{"issue":"6","key":"519_CR110","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1073\/pnas.1221891110","volume":"110","author":"K Sathasivam","year":"2013","unstructured":"Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA. 2013;110(6):2366\u201370. https:\/\/doi.org\/10.1073\/pnas.1221891110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"519_CR111","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","volume":"125","author":"RK Graham","year":"2006","unstructured":"Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125(6):1179\u201391. https:\/\/doi.org\/10.1016\/j.cell.2006.04.026.","journal-title":"Cell"},{"issue":"32","key":"519_CR112","doi-asserted-by":"publisher","first-page":"11402","DOI":"10.1073\/pnas.0503634102","volume":"102","author":"EJ Slow","year":"2005","unstructured":"Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA. 2005;102(32):11402\u20137. https:\/\/doi.org\/10.1073\/pnas.0503634102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"519_CR113","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/hmg\/dds397","volume":"22","author":"AL Southwell","year":"2013","unstructured":"Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, et al. A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet. 2013;22(1):18\u201334. https:\/\/doi.org\/10.1093\/hmg\/dds397.","journal-title":"Hum Mol Genet"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00519-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:16:48Z","timestamp":1744715808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00519-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00519-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"8 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Support for manuscript preparation and publication was provided by the University of Central Florida","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.L.S has performed preclinical sponsored research in collaboration with IONIS Pharmaceuticals and Wave Life Sciences at her current and previous academic institutions. This work has been published or publicly presented and did not include investigation of the ASO molecules discussed here. M.E.R declares no conflicts of interest. The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"M.E.R wrote the manuscript, M.E.R. and A.L.S. edited and revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}